|Cat. No. 471 005||50 µg specific antibody, lyophilized. Affinity purified with the immunogen. Albumin and azide were added for stabilization. For reconstitution add 50 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.|
Immunodetection of target molecules spotted onto a membrane.', $event)" style="cursor: help;">Dot blot: 1 : 1000 (AP staining) (see remarks) gallery
Immunoprecipitation (IP); Immunoisolation or pulldown of a target molecule using an antibody. For details and product specific hints, please refer to the ”Remarks” section.', $event)" style="cursor: help;">IP: not tested yet
Immunocytochemistry (ICC) on 4% PFA fixed cells. Immunoreactivity is usually revealed by fluorescence. Some antibodies require special fixation methods. For details, please refer to the “Remarks” section.', $event)" style="cursor: help;">ICC: not tested yet
Immunohistochemistry (IHC) on 4% PFA perfusion fixed tissue with 24h PFA post fixation. Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate. Some antibodies require special fixation methods or antigen retrieval steps. For details, please refer to the ”Remarks” section.', $event)" style="cursor: help;">IHC: 1 : 500 gallery
Immunohistochemistry (IHC-P) of formalin fixed, paraffin embedded (FFPE) tissue (some antibodies require special antigen retrieval steps, please refer to the ”Remarks” section). Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate.', $event)" style="cursor: help;">IHC-P: 1 : 1000 up to 1 : 2000 gallery
|Immunogen||Synthetic peptide comprising almost all of the processed mouse GLP-1(7-36)amide. (UniProt Id: P55095)|
Reacts with: mouse (P55095), rat (P06883).
Other species not tested yet.
|Specificity||The antibody recognizes GLP-1 with a preference for the amidated GLP-1(7-36)amide. It may show some cross-reactivity with the unprocessed precursor protein.|
Dot blot: This application was tested with synthetic peptides only.
Glucagon-like peptide-1 (GLP-1) is a member of the glucagon family of hormones.
The well conserved peptide is generated by tissue-specific posttranslational processing of the proglucagon precursor, yielding the amidated GLP-1(7-36)amide or the non-amidated GLP-1(7-37) (1). In humans and mice, GLP-1 is predominantly amidated, whereas in rats both amidated and nonamidated GLP-1 is present (1,2). Both forms are biologically active and rapidly inactivated by proteolytic cleavage (1,3).
GLP-1 is produced and secreted by intestinal enteroendocrine L-cells and certain neurons within the nucleus of the solitary tract in the brainstem in response to nutrient ingestion (1). Although there is some species variation, the density of L-cells increases distally along the gut, with greatest density in the ileum and colon (1,2).
GLP-1 exerts its effects via interaction with its specific G-protein-coupled receptor GLP-1R. Receptor binding stimulates insulin secretion from pancreatic beta cells.
In addition to its insulinotropic effects, GLP-1 promotes beta cell proliferation, it is involved in gastrointestinal motility, and it inhibits gastric emptying. In bone, GLP-1 inhibits bone resorption. In the brain, GLP-1 is thought to be involved in memory formation as well as in the control of appetite (1,3).
The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity and diabetes (4,5).